BIOCHEMISTRY;
CONFERENCE PAPER;
DECISION MAKING;
DRUG DESIGN;
DRUG FORMULATION;
EMPIRICAL RESEARCH;
KNOWLEDGE;
MEDICAL RESEARCH;
PRODUCTIVITY;
QUALITY CONTROL;
SCIENTIST;
SIMULATION;
SYSTEMS BIOLOGY;
BIOLOGICAL MODEL;
COMPUTER SIMULATION;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG SCREENING;
HUMAN;
INTERDISCIPLINARY COMMUNICATION;
ORGANIZATION AND MANAGEMENT;
BIOLOGICAL MARKERS;
BIOMEDICAL RESEARCH;
COMPUTER SIMULATION;
DRUG EVALUATION;
DRUG EVALUATION, PRECLINICAL;
DRUG INDUSTRY;
HUMANS;
INTERDISCIPLINARY COMMUNICATION;
LEGISLATION, DRUG;
MODELS, BIOLOGICAL;
SYSTEMS BIOLOGY;
Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans
Lesko L., Rowland M., Peck CC, Blashcke T. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci. 2000 ; 10 :iv-xiv.
EUFEPS conference report. Optimising drug development: Strategies to assess drug metabolism/transporter interaction potential-towards a consensus. European Federation of Pharmaceutical Sciences
Tucker GT, Houston JB, Huang SM EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. European Federation of Pharmaceutical Sciences. Eur J Pharm Sci. 2001 ; 13: 417-428.
Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development
Rolan P., Atkinson A., Lesko L. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther. 2003 ; 73: 284-291.
Getting the dose right: Report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development
Stanski DR, Rowland M., Sheiner LB Getting the dose right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development. J Pharmacokinet Pharmacodyn. 2005 ; 32: 199-211.
New safe medicines faster: A proposal for a key action within the European Union's 6th framework programme
Bjerrum OJ New safe medicines faster: a proposal for a key action within the European Union's 6th framework programme. Pharmacol Toxicol. 2000 ; 86 (suppl 1). 23-26.
Krishna R. Introduction to dose optimization. In: Krishna R, ed. Dose Optimization in Drug Development. Vol. 161. Oxford, UK: Taylor & Francis ; 2006: 1-13.
US Food and Drug Administration. Challenge and Opportunity on the Critical Path to New Medical Products. Rockville, Md: US Food and Drug Administration ; 2004. Available at: http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html. Accessed December 29, 2006.
New Safe Medicines Faster. Proposals for research topics, methodologies, techniques and other means of promoting for the drug development process to the benefit of European citizens, 2000. Available at: http://eufeps.org. Accessed December 29, 2006.
New Safe Medicines Faster. How to rethink and accelerate the development and approval of innovative new medicines for faster patient relief, 2003. Available at: http://eufeps.org. Accessed December 29, 2006.